Heron Therapeutics Gestione
Gestione criteri di controllo 2/4
Heron Therapeutics Il CEO è Craig Collard, nominato in Apr2023, ha un mandato di 1.58 anni. possiede direttamente 0.18% delle azioni della società, per un valore di $ 298.72K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.4 anni e 3.2 anni.
Informazioni chiave
Craig Collard
Amministratore delegato
US$5.5k
Compenso totale
| Percentuale dello stipendio del CEO | n/a |
| Mandato del CEO | 1.6yrs |
| Proprietà del CEO | 0.2% |
| Durata media del management | 1.4yrs |
| Durata media del Consiglio di amministrazione | 3.2yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Why Investors Shouldn't Be Surprised By Heron Therapeutics, Inc.'s (NASDAQ:HRTX) 30% Share Price Plunge
Nov 13
Investors Don't See Light At End Of Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Tunnel And Push Stock Down 30%
Nov 13Investors Don't See Light At End Of Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Tunnel And Push Stock Down 32%
Aug 08Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Share Price Boosted 31% But Its Business Prospects Need A Lift Too
May 30Heron Therapeutics: Zynrelef Potentially Eases Shareholder Pain
Apr 16Here's What Analysts Are Forecasting For Heron Therapeutics, Inc. (NASDAQ:HRTX) After Its Full-Year Results
Mar 15Heron Therapeutics, Inc. (NASDAQ:HRTX) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Feb 15Heron Therapeutics, Inc. (NASDAQ:HRTX) Held Back By Insufficient Growth Even After Shares Climb 27%
Dec 22Heron wins FDA nod for post-operative agent to address nausea and vomiting
Sep 16Is Heron Therapeutics (NASDAQ:HRTX) A Risky Investment?
Aug 10Heron Therapeutics Q2 2022 Earnings Preview
Aug 08Heron Therapeutics proposes 34% cut in workforce as part of cost reduction plan
Jun 30Heron Therapeutics: Cash Is A Problem Again
Mar 31Heron Therapeutics: Changing Strategy After Disappointing Earnings
Mar 03Health Check: How Prudently Does Heron Therapeutics (NASDAQ:HRTX) Use Debt?
Jan 19Heron Therapeutics: Looking For Signs Of The Bottom
Oct 07Is Heron Therapeutics (NASDAQ:HRTX) Using Too Much Debt?
Oct 03AMMINISTRATORE DELEGATO
Craig Collard (58 yo)
1.6yrs
Mandato
US$5,486
Compensazione
Mr. Craig Alexander Collard serves as Chief Executive Officer at Heron Therapeutics, Inc. since April 3, 2023 and its Director since February 2023. He had been Chief Executive Officer of Veloxis Pharmaceut...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Director | 1.6yrs | US$5.49k | 0.18% $ 298.7k | |
| Executive VP & CFO | 1.4yrs | US$1.76m | 0.071% $ 121.0k | |
| Executive VP & Chief Development Officer | 1.4yrs | US$1.71m | 0.068% $ 115.5k | |
| Vice President of Marketing | 1.3yrs | Nessun dato | Nessun dato | |
| Senior Vice President of Human Resources | 9.2yrs | Nessun dato | Nessun dato | |
| Senior Vice President of Oncology Care Franchise & Commercial Operations | 1.8yrs | Nessun dato | Nessun dato | |
| Chief Business Officer | less than a year | Nessun dato | Nessun dato | |
| Executive Director | no data | Nessun dato | Nessun dato |
1.4yrs
Durata media
55yo
Età media
Gestione esperta: Il team dirigenziale di HRTX non è considerato esperto (durata media 1.4 anni), il che suggerisce un nuovo team.
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Director | 1.8yrs | US$5.49k | 0.18% $ 298.7k | |
| Independent Director | 10.8yrs | US$11.02m | 0.034% $ 58.1k | |
| Independent Director | 8.4yrs | US$70.51k | 0.034% $ 58.5k | |
| Director | no data | Nessun dato | Nessun dato | |
| Independent Director | 3.2yrs | US$65.63k | 0.035% $ 59.3k | |
| Independent Chairman | 1.8yrs | US$545.53k | 0.0062% $ 10.6k | |
| Independent Director | 3.2yrs | US$55.00k | 0.035% $ 59.3k |
3.2yrs
Durata media
57yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di HRTX sono considerati esperti (durata media dell'incarico 3.2 anni).